Unfortunately, in this article in the September 2019 issue of the European Respiratory Review, figure 2 was presented incorrectly. The correct figure is presented below. The article has been corrected and republished online.
FIGURE 2.
A microRNA (miR)-21/phosphoinositide 3-kinase (PI3K)/histone deacetylase (HDAC)2 axis drives severe steroid-resistant asthma and may be targeted using miR-21 specific inhibitors (such as antagomir (Ant)-21) and/or PI3K inhibitors (such as LY294002). AAD: allergic airway disease; PTEN: phosphatase and tensin homologue.

